Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Public, Subsidiary

Established: 2002-01-25

Employees: 1K

Market Cap: -

Website: https://www.3s-guojian.com

Clinical Trials

A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma

Phase 2

Not yet recruiting

Conditions: Asthma

Interventions: Drug: 610
Drug: Placebo

First Posted Date: 2024-11-08

Last Posted Date: 2024-11-08

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 225

Registration Number: NCT06680947

Evaluation of 626 in Healthy Adult Subjects

Phase 1

Recruiting

Conditions: Healthy Subjects (HS)

Interventions: Drug: 626
Drug: Placebo

First Posted Date: 2024-11-05

Last Posted Date: 2024-12-10

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 50

Registration Number: NCT06674525

Locations: 🇨🇳
Shanghai General Hospital, Shanghai, China

A Study to Evaluate 611 in Patients with Chronic Rhinosinusitis with Nasal Polyps

Phase 3

Not yet recruiting

Conditions: Sinusitis
Nasal Polyps

Interventions: Drug: 611
Drug: Placebo

First Posted Date: 2024-10-14

Last Posted Date: 2024-10-14

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 240

Registration Number: NCT06639295

Locations: 🇨🇳
Site 01, Beijing, Beijing, China

Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis

Phase 3

Recruiting

Conditions: Dermatitis, Atopic
Eczema, Atopic

Interventions: Drug: 611
Drug: Placebo
Drug: Topical corticosteroid

First Posted Date: 2024-08-15

Last Posted Date: 2024-10-01

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 400

Registration Number: NCT06554847

Locations: 🇨🇳
Hangzhou First People's Hospital, Hangzhou, Zhejiang, China
🇨🇳
Shanghai Dermatology Hospital, Shanghai, Shanghai, China
🇨🇳
The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China

Phase I Clinical Study to Evaluate the Safety and Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors Patients

Interventions: Drug: SSGJ-706

First Posted Date: 2024-08-01

Last Posted Date: 2024-08-01

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 60

Registration Number: NCT06533605

A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients

Phase 2

Recruiting

Conditions: Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer

Interventions: Drug: SSGJ-707
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2024-07-26

Last Posted Date: 2024-10-21

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 80

Registration Number: NCT06522828

Locations: 🇨🇳
Chongqing Cancer Hospital, Chongqing, China

A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients

Phase 2

Not yet recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Bevacizumab
Drug: SSGJ-707
Drug: Oxaliplatin
Drug: Capecitabine
Drug: Calcium Folinate
Drug: 5-fluorouracil

First Posted Date: 2024-07-10

Last Posted Date: 2024-08-09

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 130

Registration Number: NCT06493760

Locations: 🇨🇳
Liu Tianshu, Shanghai, Shanghai, China

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

Phase 2

Recruiting

Conditions: First-line Advanced NSCLC Patients

Interventions: Drug: SSGJ-707
Drug: carboplatin
Drug: Pemetrexed
Drug: Paclitaxel-albumin
Drug: PD-1/L1
Drug: paclitaxel

First Posted Date: 2024-05-14

Last Posted Date: 2024-07-30

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 235

Registration Number: NCT06412471

Locations: 🇨🇳
Institute of The Hunan Cancer Hospital, Changsha, China

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors

Phase 1

Recruiting

Conditions: Locally Advanced, Recurrent or Metastatic Malignancies

Interventions: Drug: SSGJ-705

First Posted Date: 2024-04-30

Last Posted Date: 2024-10-18

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 180

Registration Number: NCT06390774

Locations: 🇨🇳
Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China

A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients

Phase 2

Recruiting

Conditions: NSCLC

Interventions: Drug: SSGJ-707

First Posted Date: 2024-04-12

Last Posted Date: 2024-05-16

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT06361927

Locations: 🇨🇳
The Hunan Cancer Hospital, Changsha, Hunan, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy